Skip to content

Clinical phenotype, multi-omics integration and Th1 immune mechanism study of vitiligo combined with autoimmune thyroid disease

Clinical phenotype, multi-omics integration and Th1 immune mechanism study of vitiligo combined with autoimmune thyroid disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127507
Enrollment
Unknown
Registered
2026-07-01
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Interventions

AITD group:None
Vitiligo combined with AITD group:None
Healthy control group:None

Sponsors

Suining Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18 - 60 years old; 2. Vitiligo group: Diagnosed as vitiligo by dermatologists based on clinical manifestations and necessary auxiliary examinations; 3. AITD group: Meets the clinical and laboratory diagnostic criteria for Hashimoto's thyroiditis or Graves' disease; 4. Vitiligo combined with AITD group: Meets the diagnostic criteria for both vitiligo and AITD simultaneously; 5. Healthy control group: Has no history of vitiligo, AITD or other clear autoimmune diseases, and no active skin diseases; 6. The subjects understood the research content and voluntarily signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Including other chronic inflammatory skin diseases, skin malignancies or systemic malignancies; 2. Including other autoimmune diseases that require systemic immunosuppressive therapy; 3. Having non-autoimmune thyroid diseases or other diseases that may significantly affect thyroid function/antibody determination; 4. Recently using systemic glucocorticoids, immunosuppressants or biological agents that may significantly affect immune indicators; 5. Subjects who the investigator deems unsuitable for participation in this study or unable to complete data collection.

Design outcomes

Primary

MeasureTime frame
Vitiligo Area Scoring Index (VASI);Vitiligo Disease Activity Score (VIDA);Type of Thyroid Disease;Thyroid Function;Thyroid Autoantibodies (TPOAb, TgAb, TRAb);

Countries

China

Contacts

Public ContactHu Yuan

Suining Central Hospital

huyuanfree@163.com+86 18717385737

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026